Anti-inflammatory and general glucocorticoid physiology in skeletal muscles affected by Duchenne muscular dystrophy : exploration of steroid-sparing agents

Autor: Arthur Rodenbach, Boel De Paepe, Sandrine Herbelet, Jan De Bleecker
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Duchenne muscular dystrophy
Osteoporosis
NF-KAPPA-B
Anti-Inflammatory Agents
PROTEIN
Review
Bioinformatics
medicine.disease_cause
lcsh:Chemistry
ACTIVATION
MDX MOUSE MODEL
Medicine and Health Sciences
steroid-sparing agents
OXIDATIVE STRESS
lcsh:QH301-705.5
Spectroscopy
MOLECULAR-MECHANISMS
TGF-BETA
General Medicine
HISTONE DEACETYLASE INHIBITORS
Computer Science Applications
medicine.anatomical_structure
Steroids
Glucocorticoid
medicine.drug
musculoskeletal diseases
Cushingoid
Catalysis
Proinflammatory cytokine
Inorganic Chemistry
TGF beta signaling pathway
medicine
Animals
Humans
Physical and Theoretical Chemistry
skeletal muscle
Muscle
Skeletal
Molecular Biology
Glucocorticoids
business.industry
Organic Chemistry
Skeletal muscle
medicine.disease
DIAPHRAGM MUSCLE
Muscular Dystrophy
Duchenne
ACETYLCYSTEINE TREATMENT
lcsh:Biology (General)
lcsh:QD1-999
glucocorticoid physiology
business
Oxidative stress
Zdroj: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 4596, p 4596 (2020)
ISSN: 1422-0067
Popis: In Duchenne muscular dystrophy (DMD), the activation of proinflammatory and metabolic cellular pathways in skeletal muscle cells is an inherent characteristic. Synthetic glucocorticoid intake counteracts the majority of these mechanisms. However, glucocorticoids induce burdensome secondary effects, including hypertension, arrhythmias, hyperglycemia, osteoporosis, weight gain, growth delay, skin thinning, cushingoid appearance, and tissue-specific glucocorticoid resistance. Hence, lowering the glucocorticoid dosage could be beneficial for DMD patients. A more profound insight into the major cellular pathways that are stabilized after synthetic glucocorticoid administration in DMD is needed when searching for the molecules able to achieve similar pathway stabilization. This review provides a concise overview of the major anti-inflammatory pathways, as well as the metabolic effects of glucocorticoids in the skeletal muscle affected in DMD. The known drugs able to stabilize these pathways, and which could potentially be combined with glucocorticoid therapy as steroid-sparing agents, are described. This could create new opportunities for testing in DMD animal models and/or clinical trials, possibly leading to smaller glucocorticoids dosage regimens for DMD patients.
Databáze: OpenAIRE
Externí odkaz: